Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
Mycobacterium tuberculosis
LORA assay
MABA assay
non-replicating M. tuberculosis
pharmacophore modeling
pretomanid derivatives
replicating M. tuberculosis
virtual screening
Journal
Journal of biomolecular structure & dynamics
ISSN: 1538-0254
Titre abrégé: J Biomol Struct Dyn
Pays: England
ID NLM: 8404176
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
pubmed:
28
1
2020
medline:
29
6
2021
entrez:
28
1
2020
Statut:
ppublish
Résumé
Pretomanid (PA-824) is the recently (2019) approved drug for the treatment of extensively drug-resistant (XDR) TB and the multidrug-resistant (MDR) TB by US FDA. The experimental data of antitubercular activity of 543 pretomanid derivatives (total 6 datasets) against replicating (active) and non-replicating (dormant) forms of
Identifiants
pubmed: 31983295
doi: 10.1080/07391102.2020.1719205
doi:
Substances chimiques
Antitubercular Agents
0
Nitroimidazoles
0
pretomanid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM